Latest from Huntsman Cancer Institute

A new study has provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.
Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.
With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.
Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.
Due to the unique characteristics of adolescents and young adults, there is a growing effort to address their oncology needs.
Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.
In this segment, the panel members share their thoughts on use of checkpoint inhibitors for first-line treatment of advanced melanoma.
In this segment, John Sweetenham, MD, and Robert Chen, MD, comment on various agents currently being investigated in the treatment of Hodgkin lymphoma.
Publication Bottom Border
Border Publication